Brian I Carr

Summary

Publications

  1. ncbi Effects of low concentrations of regorafenib and sorafenib on human HCC cell AFP, migration, invasion, and growth in vitro
    Brian I Carr
    Laboratory of Biochemistry, National Institute for Digestive Diseases, IRCCS S De Bellis, Castellana Grotte BA, Italy
    J Cell Physiol 228:1344-50. 2013
  2. ncbi Fluoro-Sorafenib (Regorafenib) effects on hepatoma cells: growth inhibition, quiescence, and recovery
    Brian I Carr
    Laboratory of Biochemistry, National Institute for Digestive Diseases, IRCCS Saverio de Bellis, Castellana Grotte, Italy
    J Cell Physiol 228:292-7. 2013
  3. ncbi Some new approaches to the management of hepatocellular carcinoma
    Brian I Carr
    IRCCS de Bellis National Institute for Digestive Diseases, Castellana Grotte, BA, Italy
    Semin Oncol 39:369-73. 2012
  4. ncbi Peripheral blood lymphocyte depletion after hepatic arterial 90Yttrium microsphere therapy for hepatocellular carcinoma
    Brian I Carr
    Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
    Int J Radiat Oncol Biol Phys 82:1179-84. 2012
  5. ncbi Significance of increased serum GGTP levels in HCC patients
    Brian I Carr
    Liver Tumor Program, Kimmel Cancer Center, Thomas Jefferson University, Bluemle Building, Room 519, 233 S 10th Street, Philadelphia, PA 19107, USA
    Hepatogastroenterology 57:869-74. 2010
  6. ncbi Differential effects of vitamin K1 on AFP and DCP levels in patients with unresectable HCC and in HCC cell lines
    Brian I Carr
    Department of Medical Oncology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA
    Dig Dis Sci 56:1876-83. 2011
  7. ncbi Chemoembolization for unresectable hepatocellular carcinoma in patients with or without portal vein thrombosis
    Brian I Carr
    University of Pittsburgh Medical Center, Dept of Medical Oncology, Thomas Jefferson University, Philadelphia, USA
    Hepatogastroenterology 57:1375-81. 2010
  8. ncbi HCC in young adults
    Brian I Carr
    Liver Tumor Program, Kimmel Cancer Center, Dept of Medical Oncology, Thomas Jefferson University, Bluely Building, Room 519, 233 S 10th Street, Philadelphia, PA 19107, USA
    Hepatogastroenterology 57:436-40. 2010
  9. ncbi c-Met-Akt pathway-mediated enhancement of inhibitory c-Raf phosphorylation is involved in vitamin K1 and sorafenib synergy on HCC growth inhibition
    Brian I Carr
    De Bellis Medical Research Institute, Castellana Grotte, Italy
    Cancer Biol Ther 12:531-8. 2011
  10. ncbi Prospective randomized trial of hepatic artery chemotherapy with cisplatin and doxorubicin, with or without lipiodol in the treatment of advanced stage hepatocellular carcinoma
    Brian Irving Carr
    Department of Liver Transplantation, University of Pittsburgh, Pittsburgh, PA, USA
    J Clin Gastroenterol 45:e87-91. 2011

Detail Information

Publications73

  1. ncbi Effects of low concentrations of regorafenib and sorafenib on human HCC cell AFP, migration, invasion, and growth in vitro
    Brian I Carr
    Laboratory of Biochemistry, National Institute for Digestive Diseases, IRCCS S De Bellis, Castellana Grotte BA, Italy
    J Cell Physiol 228:1344-50. 2013
    ..Evidence was also found for changes in cell signaling pathways in these slow-growth cells. Low multikinase inhibitor concentrations thus modulate several aspects of HCC cell biology...
  2. ncbi Fluoro-Sorafenib (Regorafenib) effects on hepatoma cells: growth inhibition, quiescence, and recovery
    Brian I Carr
    Laboratory of Biochemistry, National Institute for Digestive Diseases, IRCCS Saverio de Bellis, Castellana Grotte, Italy
    J Cell Physiol 228:292-7. 2013
    ..Cells surviving Regorafenib treatment remain viable, but quiescent and capable of regrowth following drug removal. The reversibility of tumor cell growth suppression after drug removal may have clinical implications...
  3. ncbi Some new approaches to the management of hepatocellular carcinoma
    Brian I Carr
    IRCCS de Bellis National Institute for Digestive Diseases, Castellana Grotte, BA, Italy
    Semin Oncol 39:369-73. 2012
    ....
  4. ncbi Peripheral blood lymphocyte depletion after hepatic arterial 90Yttrium microsphere therapy for hepatocellular carcinoma
    Brian I Carr
    Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
    Int J Radiat Oncol Biol Phys 82:1179-84. 2012
    ..The short- and long-term effects of (90)Yttrium microspheres therapy for hepatocellular carcinoma (HCC) on peripheral blood lymphocytes are unknown and were therefore examined...
  5. ncbi Significance of increased serum GGTP levels in HCC patients
    Brian I Carr
    Liver Tumor Program, Kimmel Cancer Center, Thomas Jefferson University, Bluemle Building, Room 519, 233 S 10th Street, Philadelphia, PA 19107, USA
    Hepatogastroenterology 57:869-74. 2010
    ..The results suggest that following trends in serum GGTP levels, in the context of specific ranges of AFP and bilirubin levels, might be useful in diagnosis of small HCCs...
  6. ncbi Differential effects of vitamin K1 on AFP and DCP levels in patients with unresectable HCC and in HCC cell lines
    Brian I Carr
    Department of Medical Oncology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA
    Dig Dis Sci 56:1876-83. 2011
    ..DCP is a useful HCC tumor marker, which reflects a defect in vitamin K metabolism. We tested the hypothesis that vitamin K treatment of HCC patients might suppress this marker and possibly AFP also...
  7. ncbi Chemoembolization for unresectable hepatocellular carcinoma in patients with or without portal vein thrombosis
    Brian I Carr
    University of Pittsburgh Medical Center, Dept of Medical Oncology, Thomas Jefferson University, Philadelphia, USA
    Hepatogastroenterology 57:1375-81. 2010
    ..Chemoembolization in the presence of portal vein thrombosis (PVT) is thought to be hazardous and such patients are regarded as prognostically poor...
  8. ncbi HCC in young adults
    Brian I Carr
    Liver Tumor Program, Kimmel Cancer Center, Dept of Medical Oncology, Thomas Jefferson University, Bluely Building, Room 519, 233 S 10th Street, Philadelphia, PA 19107, USA
    Hepatogastroenterology 57:436-40. 2010
    ....
  9. ncbi c-Met-Akt pathway-mediated enhancement of inhibitory c-Raf phosphorylation is involved in vitamin K1 and sorafenib synergy on HCC growth inhibition
    Brian I Carr
    De Bellis Medical Research Institute, Castellana Grotte, Italy
    Cancer Biol Ther 12:531-8. 2011
    ....
  10. ncbi Prospective randomized trial of hepatic artery chemotherapy with cisplatin and doxorubicin, with or without lipiodol in the treatment of advanced stage hepatocellular carcinoma
    Brian Irving Carr
    Department of Liver Transplantation, University of Pittsburgh, Pittsburgh, PA, USA
    J Clin Gastroenterol 45:e87-91. 2011
    ..This randomized study assessed the responses in hepatocellular carcinoma (HCC) to hepatic arterial doxorubicin plus cisplatin, with or without lipiodol...
  11. ncbi Novel hydroxyl naphthoquinones with potent Cdc25 antagonizing and growth inhibitory properties
    Vincent P Peyregne
    Liver Cancer Center, Starzl Transplantation Institute, Department of Surgery, University of Pittsburgh School of Medicine, E1552 Biomedical Science Tower, 200 Lothrop Street, Pittsburgh, PA 15213
    Mol Cancer Ther 4:595-602. 2005
    ..These two new compounds may be useful probes for the biological functions of Cdc25s and have the potential for disrupting the cell cycle of growing tumor cells...
  12. ncbi Phosphorylation regulates Myc expression via prolonged activation of the mitogen-activated protein kinase pathway
    Ziqiu Wang
    Thomas E Starzl Transplant Institute, Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA
    J Cell Physiol 208:133-40. 2006
    ..These data suggest that an increase in c-Myc phosphorylation in response to prolonged ERK phosphorylation negatively auto-regulates c-Myc gene expression, leading to the suppression of its target gene expression and cell cycle block...
  13. ncbi Hepatocyte growth factor enhances protein phosphatase Cdc25A inhibitor compound 5-induced hepatoma cell growth inhibition via Akt-mediated MAPK pathway
    Ziqiu Wang
    Thomas E Starzl Transplantation Institute, Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA
    J Cell Physiol 203:510-9. 2005
    ....
  14. ncbi Sorafenib combined vitamin K induces apoptosis in human pancreatic cancer cell lines through RAF/MEK/ERK and c-Jun NH2-terminal kinase pathways
    Gang Wei
    Department of Medical Oncology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
    J Cell Physiol 224:112-9. 2010
    ..Since both agents are available for human use, the combination is attractive for evaluation against pancreas cancer growth in vivo...
  15. ncbi Cdc25A and ERK interaction: EGFR-independent ERK activation by a protein phosphatase Cdc25A inhibitor, compound 5
    Ziqiu Wang
    Thomas E Starzl Transplant Institute, Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    J Cell Physiol 204:437-44. 2005
    ..These data suggest that phospho-ERK is likely another Cdc25A substrate, and Cpd 5-caused ERK phosphorylation is probably regulated by both EGFR-dependent and EGFR-independent pathways...
  16. ncbi Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo
    Gang Wei
    Department of Medical Oncology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Int J Cancer 127:2949-58. 2010
    ..Thus, each agent can antagonize Raf: sorafenib as a direct inhibitor and VK1 through inhibitory Raf phosphorylation. As both agents are available for human use, the combination has potential for improving sorafenib effects in HCC...
  17. ncbi Fluorinated Cpd 5, a pure arylating K-vitamin derivative, inhibits human hepatoma cell growth by inhibiting Cdc25 and activating MAPK
    Siddhartha Kar
    Liver Cancer Center, Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh PA, USA
    Biochem Pharmacol 72:1217-27. 2006
    ..F-Cpd 5 thus differentially inhibited growth of normal and tumor cells by preferentially inhibiting the actions of Cdc25A and Cdc25B phosphatases and inducing MAPK phosphorylation...
  18. ncbi H32, a non-quinone sulfone analog of vitamin K3, inhibits human hepatoma cell growth by inhibiting Cdc25 and activating ERK
    Siddhartha Kar
    Liver Cancer Center, T E Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, USA
    Cancer Biol Ther 5:1340-7. 2006
    ..Thus, H32 differentially inhibited growth of normal and liver tumor cells by preferentially inhibiting the actions of Cdc25 phosphatases and inducing persistent ERK phosphorylation...
  19. ncbi Cancer-related symptom clusters, eosinophils, and survival in hepatobiliary cancer: an exploratory study
    Jennifer L Steel
    Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA
    J Pain Symptom Manage 39:859-71. 2010
    ..The study of symptom clusters is gaining increased attention in the field of oncology in an attempt to improve the quality of life of patients diagnosed with cancer...
  20. ncbi Transient and sustained ERK phosphorylation and nuclear translocation in growth control
    Takahito Adachi
    Department of Surgery, Thomas E. Starzl Transplantation Institute, University of Pittsburgh, Pennsylvania 15213, USA
    J Cell Physiol 192:151-9. 2002
    ....
  21. ncbi Growth inhibitory actions of prothrombin on normal hepatocytes: influence of matrix
    Brian I Carr
    Liver Cancer Center, Starzl Transplantation Institute, University of Pittsburgh, E1552 Biomedical Science Tower, 200 Lothrop Street, Pittsburgh, PA 15260, USA
    Cell Biol Int 31:929-38. 2007
    ..Hepatomas resist this action, possibly due to their different matrix proteins. This represents a novel mechanism for growth regulation and provides a possible biological significance for the tumor marker DCP...
  22. ncbi Involvement of ATM-mediated Chk1/2 and JNK kinase signaling activation in HKH40A-induced cell growth inhibition
    Ziqiu Wang
    Department of Medical Oncology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
    J Cell Physiol 221:213-20. 2009
    ..Our data support the hypothesis that binding of HKH40A to cellular DNA likely activates ATM kinase, which then induces parallel Chk 1/2 and JNK signaling pathways, leading to G2/M cell cycle block and apoptosis...
  23. ncbi 2-Methoxyestradiol inhibits hepatocellular carcinoma cell growth by inhibiting Cdc25 and inducing cell cycle arrest and apoptosis
    Siddhartha Kar
    University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
    Cancer Chemother Pharmacol 62:831-40. 2008
    ..The exact mechanisms of its action are still unclear. We have studied the mechanisms of growth inhibition of several of human and rat hepatoma and normal liver cells by 2-ME...
  24. ncbi JS-K, a novel non-ionic diazeniumdiolate derivative, inhibits Hep 3B hepatoma cell growth and induces c-Jun phosphorylation via multiple MAP kinase pathways
    Zhenggang Ren
    Liver Cancer Center, Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA
    J Cell Physiol 197:426-34. 2003
    ..The data support the idea that prolonged MAPK activation by JS-K action is important in mediating its growth-inhibitory actions. JS-K thus represents a promising platform for novel growth inhibitory analog synthesis...
  25. ncbi Treatment of unresectable cholangiocarcinoma with gemcitabine-based transcatheter arterial chemoembolization (TACE): a single-institution experience
    Niraj J Gusani
    Division of Surgical Oncology, Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
    J Gastrointest Surg 12:129-37. 2008
    ..We report our experience treating cholangiocarcinoma with TACE using chemotherapeutic regimens based on the well-tolerated drug gemcitabine...
  26. ncbi Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study
    Brian I Carr
    Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA
    Cancer 116:1305-14. 2010
    ..TACE has demonstrated the ability to prolong survival. However, long-term survival remains uncertain...
  27. ncbi PM-20, a novel inhibitor of Cdc25A, induces extracellular signal-regulated kinase 1/2 phosphorylation and inhibits hepatocellular carcinoma growth in vitro and in vivo
    Siddhartha Kar
    Liver Cancer Center, Starzl Transplantation Institute, University of Pittsburgh, 200 Lothrop Street, Pittsburgh, PA 15260, USA
    Mol Cancer Ther 5:1511-9. 2006
    ..PM-20 thus represents a novel class of tumor growth inhibitor that inhibits mainly Cdc25A, is dependent on ERK activation, and has a considerable margin of selectivity for tumor cells compared with normal cells...
  28. ncbi Hepatocellular carcinoma: current management and future trends
    Brian I Carr
    Liver Cancer Center, Starzl Transplantation Institute, University of Pittsburgh Medical Center, BST, E 1552, 200 Lothrop Street, Pittsburgh, Pennsylvania 15213, USA
    Gastroenterology 127:S218-24. 2004
    ..Newly emerging agents with promise include 90 Y microspheres, antiangiogenesis agents, inhibitors of growth factors and their receptors, and K vitamins...
  29. ncbi 90Y microsphere treatment of unresectable liver metastases: changes in 18F-FDG uptake and tumour size on PET/CT
    Maren Bienert
    Department of Radiology, University of Pittsburgh Medical Center (UPMC, 200 Lothrop Street, Pittsburgh, PA 15213, USA
    Eur J Nucl Med Mol Imaging 32:778-87. 2005
    ..CONCLUSION: The metabolic information obtained from FDG-PET/CT seems to provide a more accurate and earlier assessment of therapy response following 90Y microsphere treatment than does the anatomical CT information...
  30. ncbi Naturally occurring K vitamins inhibit pancreatic cancer cell survival through a caspase-dependent pathway
    Shayna L Showalter
    Department of Surgery, Jefferson Center for Pancreatic, Biliary and Related Cancers, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
    J Gastroenterol Hepatol 25:738-44. 2010
    ..We hypothesized that the well-tolerated and naturally occurring VK1 and VK2 may be used to inhibit pancreatic cancer cell survival...
  31. ncbi A Cdc25A antagonizing K vitamin inhibits hepatocyte DNA synthesis in vitro and in vivo
    Brian I Carr
    Department of Surgery, University of Pittsburgh, Pittsburgh, PA 15213, USA
    J Mol Biol 326:721-35. 2003
    ..Cdc25A inhibitors may thus be useful for defining biochemical pathways involving protein tyrosine phosphorylation that mediate cell growth inhibition...
  32. ncbi Integrin alpha5-induced EGFR activation by prothrombin triggers hepatocyte apoptosis via the JNK signaling pathway
    Ziqiu Wang
    Department of Medical Oncology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
    J Cell Physiol 216:551-7. 2008
    ..The data suggest that integrin-related EGFR activation by prothrombin can induce cell growth inhibition and apoptosis via an EGFR-JNK signaling pathway...
  33. ncbi K vitamins, PTP antagonism, and cell growth arrest
    Brian I Carr
    Liver Cancer Center, Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15213, USA
    J Cell Physiol 193:263-74. 2002
    ..It is clearly associated with prolonged ERK1/2 phosphorylation, which is in contrast with the transient ERK1/2 phosphorylation induced by growth stimulatory mitogens...
  34. ncbi Identification of epidermal growth factor receptor as a target of Cdc25A protein phosphatase
    Ziqiu Wang
    Thomas E Starzl Transplantation Institute, Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA
    J Biol Chem 277:19470-5. 2002
    ..These data link the cell cycle control Cdc25A phosphatase to an EGFR-linked mitogenic signaling pathway specifically involving EGFR dephosphorylation...
  35. ncbi Inhibition of rat liver regeneration after partial hepatectomy and induction of ERK phosphorylation by Cpd 5, a K vitamin-based anticancer compound
    Siddhartha Kar
    Department of Surgery, Liver Cancer Center, Starzl Transplantation Institute, University of Pittsburgh, E1552 Biomedical Science Tower, 200 Lothrop Street, Pittsburgh, PA 15260, USA
    Carcinogenesis 25:2345-51. 2004
    ..These results show that induction of ERK2 phosphorylation is likely involved in the mechanism by which Cpd 5 inhibits PH-induced DNA synthesis, probably as a result of its ability to inhibit the activity of ERK phosphatase(s)...
  36. ncbi Involvement of receptor tyrosine phosphatase DEP-1 mediated PI3K-cofilin signaling pathway in sorafenib-induced cytoskeletal rearrangement in hepatoma cells
    Ziqiu Wang
    Department of Medical Oncology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
    J Cell Physiol 224:559-65. 2010
    ..Our data provide evidence that besides inhibition of the Raf-MAPK pathway, Sorafenib might also regulate hepatoma cell growth via alteration of receptor-mediated cytoskeletal rearrangement...
  37. ncbi Outcome of 1000 liver cancer patients evaluated at the UPMC Liver Cancer Center
    David A Geller
    Department of Surgery, Thomas E Starzl Transplantation Institute, University of Pittsburgh, PA 15213, USA
    J Gastrointest Surg 10:63-8. 2006
    ..The most common reason for offering palliative care was hepatic insufficiency usually associated with cirrhosis...
  38. ncbi Antitumor and anticarcinogenic actions of Cpd 5: a new class of protein phosphatase inhibitor
    Siddhartha Kar
    Starzl Transplantation Institute, Liver Cancer Center, Departments of Surgery and Chemistry, University of Pittsburgh, Pittsburgh, PA 15260, USA
    Carcinogenesis 24:411-6. 2003
    ..This is the first report of the in vivo activity and growth inhibitory mechanism of a novel class of K vitamin growth inhibitors that have potent tyrosine phosphatase activity...
  39. ncbi Involvement of c-Myc in growth inhibition of Hep 3B human hepatoma cells by a vitamin K analog
    Lisheng Ge
    Department of Surgery, Liver Cancer Center, Starzl Transplant Institute, School of Medicine, University of Pittsburgh, E1552 Biomedical Science Tower, 200 Lothrop Street, Pittsburgh, PA 15213, USA
    J Hepatol 41:823-9. 2004
    ..CONCLUSIONS: The results suggest that Cpd 5-mediated c-Myc phosphorylation resulted in enhanced c-Myc protein degradation and reduced c-Myc protein levels, which may contribute to cell growth inhibition by Cpd 5...
  40. ncbi Grb2-associated binder-1 plays a central role in the hepatocyte growth factor enhancement of hepatoma growth inhibition by K vitamin analog compound 5
    Ziqiu Wang
    Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Hepatology 46:2003-13. 2007
    ..CONCLUSION: Gab1 plays a central role in regulating HGF/Cpd 5 synergy in their actions on Hep3B cell growth inhibition...
  41. ncbi Binding and inhibition of Cdc25 phosphatases by vitamin K analogues
    Siddhartha Kar
    Department of Surgery, Liver Cancer Center, Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, USA
    Biochemistry 42:10490-7. 2003
    ..The results demonstrate a direct interaction and binding between this growth-inhibiting K vitamin derivative with both purified as well as with cellular Cdc25A, Cdc25B, and Cdc25C...
  42. ncbi Small hepatocellular carcinomas and thrombocytopenia
    Brian I Carr
    Department of Nutritional Carcinogenesis, IRCCS De Bellis, National Institute for Digestive Diseases, Castellana Grotte, Italy brianicarr hotmail com
    Oncology 83:331-8. 2012
    ..Clinical phenotypes of small and large hepatocellular carcinomas (HCCs) are not well characterized...
  43. ncbi Preliminary results of an individually tailored psychosocial intervention for patients with advanced hepatobiliary carcinoma
    Jennifer L Steel
    University of Pittsburgh School of Medicine, Starzl Transplantation Institute, Liver Cancer Center, 3459 Fifth Avenue, Montefiore S, Pittsburgh, PA 15213, USA
    J Psychosoc Oncol 25:19-42. 2007
    ..A plethora of research now exists documenting the benefits of psychosocial interventions for cancer patients; however, no studies have been conducted with people diagnosed with hepatobiliary carcinoma...
  44. ncbi One year survival with poorly differentiated metastatic pancreatic carcinoma following chemoembolization with gemcitabine and cisplatin
    Daniel B Brown
    Division of Interventional Radiology, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Oncol Rep 24:767-9. 2010
    ..Given the typical survival of 6 months or less in this patient group with standard therapies, further research is warranted...
  45. ncbi Low alpha-fetoprotein hepatocellular carcinoma
    Brian I Carr
    Liver Tumor Program of Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
    J Gastroenterol Hepatol 25:1543-9. 2010
    ..A large proportion of hepatocellular carcinoma (HCC) patients do not secrete elevated levels of the tumor marker alpha-fetoprotein (AFP). There is little published guide to prognostic features of this patient subset...
  46. ncbi Tumor and liver determinants of prognosis in unresectable hepatocellular carcinoma: a case cohort study
    Brian I Carr
    Liver Tumor Program of Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA
    J Gastroenterol Hepatol 23:1259-66. 2008
    ..A total of 967 patients with unresectable and untransplantable, biopsy-proven hepatocellular carcinoma (HCC) were prospectively evaluated at baseline and followed up till death...
  47. ncbi Hepatic artery chemoembolization for advanced stage HCC: experience of 650 patients
    Brian I Carr
    Liver Cancer Center, Thomas E Starzl Transplant Institute, University of Pittsburgh, Pittsburgh, PA 15213, USA
    Hepatogastroenterology 49:79-86. 2002
    ..Good liver function and tumor vascularity are associated with response to chemotherapy, which in turn is associated with enhanced survival. Many deaths are due to cirrhosis and not hepatocellular carcinoma...
  48. ncbi Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients
    Brian I Carr
    Liver Cancer Center, Starzl Transplantation Institute, Pittsburgh, PA 15213, USA
    Liver Transpl 10:S107-10. 2004
    ..There were 42 deaths, 21 due to liver failure, 6 from HCC progression, and 3 from metastases. Therasphere appears to be a relatively safe and effective therapy for advanced-stage unresectable HCC...
  49. ncbi Measuring post-traumatic growth in people diagnosed with hepatobiliary cancer: directions for future research
    Jennifer L Steel
    Department of Surgery, Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pennsylvania, USA
    Oncol Nurs Forum 35:643-50. 2008
    ..To highlight and provide preliminary data regarding issues in the measurement of post-traumatic growth in people diagnosed with primary or metastatic hepatobiliary cancer...
  50. ncbi alpha-Thrombin inhibits DNA synthesis in rat hepatocytes but not in hepatoma cells by receptor activation and proteolysis
    Siddhartha Kar
    Liver Cancer Center, T E Starzl Transplantation Institute, University of Pittsburgh Medical Center, E1550, BST, Pittsburgh, PA 15260, USA
    Mol Cell Biochem 304:189-97. 2007
    ..However, no appreciable cell detachment was observed. These results suggest a role of alpha-thrombin as a potent growth inhibitor of normal hepatocytes, possibly through control of fibronectin or other matrix protein(s)...
  51. ncbi A simple prognostic scoring system for patients with unresectable hepatocellular carcinoma treated by chemo-embolization
    Igor Dvorchik
    Liver Cancer Center, Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, PA 15260, USA
    Cancer Detect Prev 31:154-60. 2007
    ..Hepatocellular carcinoma (HCC) comprises heterogeneous groups of patients with differing outcomes...
  52. ncbi Depression, immunity, and survival in patients with hepatobiliary carcinoma
    Jennifer L Steel
    University of Pittsburgh School of Medicine, Liver Cancer Center, Department of Surgery, Starzl Transplantation Institute, Pittsburgh, PA 15213, USA
    J Clin Oncol 25:2397-405. 2007
    ....
  53. ncbi Evaluation of responses to chemoembolization in patients with unresectable hepatocellular carcinoma
    Osama M Ebied
    Department of Radiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
    Cancer 97:1042-50. 2003
    ..However, even patients classified by CT as hypervascular nonresponders and hypovascular responders have improved survival...
  54. ncbi Clinical evaluation of lens culinaris agglutinin-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin in histologically proven hepatocellular carcinoma in the United States
    Brian I Carr
    Liver Cancer Center, Starzl Transplantation Institute, University of Pittsburgh Medical Center, E1552 BST, 200 Lothrop Street, Pittsburgh, Pennsylvania 15213, USA
    Dig Dis Sci 52:776-82. 2007
    ..AFP-L3% was significantly related to portal vein invasion and patient outcomes and appears to be a useful prognostic marker for HCC...
  55. ncbi The effects of hepatic artery chemotherapy on viral hepatitis in patients with hepatocellular carcinoma
    Jawad Ahmad
    Liver Cancer Center, Starzl Transplant Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15213, USA
    Dig Dis Sci 50:331-5. 2005
    ..The presence of chronic viral hepatitis with normal bilirubin should not exclude the use of these therapies in patients with unresectable HCC...
  56. ncbi Health-related quality of life: Hepatocellular carcinoma, chronic liver disease, and the general population
    Jennifer L Steel
    University of Pittsburgh School of Medicine Starlz Transplantation Institute, Liver Cancer Center, 3459 Fifth Avenue Montefiore 7 S, Pittsburgh, PA 15213, USA
    Qual Life Res 16:203-15. 2007
    ..Furthermore, people with CLD reported equivalent emotional well-being as the general population sample. HRQL subscale scores, with the exception of social and family well-being, discriminated group membership...
  57. ncbi Posttraumatic growth, immunity and survival in patients with hepatoma
    James T Dunigan
    Department of Medicine, Division of Rheumatology and Immunology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA
    Dig Dis Sci 52:2452-9. 2007
    ..Further research is warranted regarding the possible immune mediation between PTG and survival...
  58. ncbi Hepatic artery chemoembolization for the treatment of liver metastases from neuroendocrine tumors: a long-term follow-up in 123 patients
    Xiang Da Dong
    UPMC Liver Cancer Center, University of Pittsburgh, Starzl Transplant Institute, 3459 Fifth Avenue, UPMC Montefiore, 7 South, Pittsburgh, PA 15213, USA
    Med Oncol 28:S286-90. 2011
    ..003). Chemoembolization for unresectable NETs metastatic to liver is useful for tumor size reduction, symptom palliation and can be associated with prolonged survival...
  59. ncbi Pain at presentation and survival in hepatocellular carcinoma
    Brian I Carr
    Department of Medical Oncology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
    J Pain 11:988-93. 2010
    ..Results of this study could inform future research and clinical investigations regarding the importance of pain at presentation in patients with HCC, which impacts qualify of life and survival...
  60. ncbi Persistent ERK phosphorylation negatively regulates cAMP response element-binding protein (CREB) activity via recruitment of CREB-binding protein to pp90RSK
    Ziqiu Wang
    Liver Cancer Center, Thomas E Starzl Transplantation Institute, Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA
    J Biol Chem 278:11138-44. 2003
    ..These data provide evidence that CBP.RSK complex formation in response to persistent ERK phosphorylation by Cpd 5 down-regulates CREB activity, leading to inhibition of both cAMP response element-mediated gene expression and cell growth...
  61. ncbi Chemo-embolization for unresectable hepatocellular carcinoma with different sizes of embolization particles
    Nikhil B Amesur
    Department of Radiology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
    Dig Dis Sci 53:1400-4. 2008
    ..For 100-300-microm particles: 1 and 3 treatments, 60% and 88% of patients. For 300-500-microm particles: 1 and 3 treatments, 50% and 57% of patients. It was concluded the 100-300-microm EMBS particles produce slightly higher responses...
  62. ncbi NAD(P)H:quinone oxidoreductase-1-dependent and -independent cytotoxicity of potent quinone Cdc25 phosphatase inhibitors
    Yusheng Han
    Department of Pharmacology, Hillman Cancer Center, University of Pittsburgh Cancer Institute, 5117 Centre Avenue, Pittsburgh, PA 15213, USA
    J Pharmacol Exp Ther 309:64-70. 2004
    ..Thus, NQO1 detoxified Cpd 5, probably by reducing it to a less active hydroquinone, whereas NSC 95397- and NSC 663284-generated cytotoxicity was unaffected by NQO1...
  63. ncbi Economic evaluation of sorafenib in unresectable hepatocellular carcinoma
    Brian I Carr
    Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
    J Gastroenterol Hepatol 25:1739-46. 2010
    ..The aim of this study was to assess the cost-effectiveness of sorafenib versus best supportive care in the treatment of advanced hepatocellular carcinoma in the USA...
  64. ncbi Sequential FDG PET/CT in 90Y microsphere treatment of unresectable colorectal liver metastases
    Maren Bienert
    Department of Radiology, University of Pittsburgh Medical Center (UPMC, 200 Lothrop Street, Pittsburgh, PA 15213, USA
    Eur J Nucl Med Mol Imaging 32:723. 2005
  65. ncbi Small HCCs identified by screening
    Petr Pancoska
    Center for Clinical Pharmacology, University of Pittsburgh, Pittsburgh, PA, USA
    Dig Dis Sci 56:3078-85. 2011
    ..Survival in HCC depends on diagnosis at early tumor stage, best achieved through surveillance radiology. There is also a need for complementary serum tests...
  66. ncbi HCC in older patients
    Brian I Carr
    Department of Medical Oncology, Liver Tumor Program, Kimmel Cancer Center, Thomas Jefferson University, Bluemle Building, Room 1002, 233 S 10th Street, Philadelphia, PA 19107, USA
    Dig Dis Sci 55:3584-90. 2010
    ..Hepatocellular carcinoma (HCC) is a heterogeneous disease, with many poorly-defined prognostic patient subsets. Identification of discrete subsets will aid rational patient and treatment selection...
  67. ncbi Network-based analysis of survival for unresectable hepatocellular carcinoma
    Petr Pancoska
    Center for Clinical Pharmacology, University of Pittsburgh, Pittsburgh, PA, USA
    Semin Oncol 37:170-81. 2010
    ..The identification of phenotypic groups of HCC may be of value in studies designed to understand their underlying pathophysiology. We conclude that NPA offers a new useful tool in the reclassification of HCC...
  68. ncbi Hepatobiliary effects of 90yttrium microsphere therapy for unresectable hepatocellular carcinoma
    Michael A Nalesnik
    Thomas E Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
    Hum Pathol 40:125-34. 2009
    ..The pathologist should be aware of these changes to distinguish them from the diffuse "radiation hepatitis" associated with older forms of radiotherapy...
  69. ncbi EGFR-independent activation of ERK1/2 mediates growth inhibition by a PTPase antagonizing K-vitamin analog
    Siddhartha Kar
    Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15260, USA
    J Cell Physiol 190:356-64. 2002
    ..This is likely due to the observed antagonism of ERK phosphatase activity. A candidate PTPase was found to be Cdc25A, a recently identified ERK phosphatase...
  70. ncbi Proxy ratings of health related quality of life in patients with hepatocellular carcinoma
    Jennifer L Steel
    University of Pittsburgh Medical Center, USA
    Qual Life Res 14:1025-33. 2005
    ..Further research is warranted with larger samples...
  71. ncbi Sexual functioning in patients with hepatocellular carcinoma
    Jennifer Steel
    Department of Surgery, Liver Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA
    Cancer 104:2234-43. 2005
    ..CONCLUSIONS: Although a large percentage of sexual dysfunction may have been secondary to comorbid medical problems and medications, treatment of the sexual dysfunction is still warranted...
  72. ncbi Hepatocellular carcinoma in noncirrhotic liver: CT, clinical, and pathologic findings in 39 U.S. residents
    Giuseppe Brancatelli
    Department of Radiology, University of Pittsburgh Medical Center, 200 Lothrop St, Pittsburgh, PA 15213, USA
    Radiology 222:89-94. 2002
    ..CONCLUSION: HCC developed in the absence of cirrhosis or known risk factors and typically appeared as a large symptomatic hepatic tumor with clinical, laboratory, and CT features that distinguish it from most other hepatic masses...
  73. ncbi Induction of apoptosis via mitogen-activated protein kinase pathway by a K vitamin analog in rat hepatocytes
    Ziqiu Wang
    Thomas E. Starzl Transplantation Institute, Department of Surgery, University of Pittsburgh School of Medicine, E 1552 Biomedical Science Tower, 200 Lothrop Street, Pittsburgh, PA 15213, USA
    J Hepatol 36:85-92. 2002
    ..CONCLUSIONS: The data suggest that the ERK signaling pathway may be involved in the regulation of rat hepatocyte apoptosis induced by Cpd 5...